COVID-19
Conditions
Interventions
Ivermectin
Standard of Care
Sponsors
LAGOS STATE MINISTRY OF HEALTH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Provide written informed consent prior to initiation of any study procedures (2) Understand and agree to comply with planned study procedures (3) Agree to the collection of oropharyngeal swabs and venous blood per protocol (4) Be male or non-pregnant female adult =18 years of age at time of enrolment (5) Have laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen no more than 72 hours prior to randomisation.
Exclusion criteria
Exclusion criteria: 1. American Society of Anaesthesiologists (ASA) class 3 and above. 2. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 3. Pregnant or breast feeding. 4. Anticipated transfer to another facility which is not a study site within 72 hours. 5. Participants with known haematological diseases (G6PD deficiency) 6. Participants with chronic liver and kidney disease and reaching end-stage. 7. Participants with arrhythmia and chronic heart disease. 8. Participants known to have retinal disease or hearing loss. 9. Participants known to have a mental illness. 10. Skin disorders (including rash, dermatitis, psoriasis). 11. Allergy to Ivermectin or its analogues.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Resolution of symptoms assessed by clinical status and daily NEWS score until discharge and on ; 2. SARS-CoV-2 clearance time | — |
Countries
Nigeria
Contacts
Public ContactHussein AbdurRazzaq
Head Health Research Unit
Outcome results
None listed